
Allergan's recently announced $600 million settlement to resolve federal charges that it marketed Botox (onabotulinumtoxinA) for unapproved uses could hinder innovation and hamper patient care, some dermatologists worry. But in the long term, sources agree that the settlement will have little impact on the fortunes of the drug or its maker.
